Japan’s health ministry approved a slew of new medicines on September 25 including multiple “first of its kind” products, among them being GlaxoSmithKline’s respiratory syncytial virus (RSV) vaccine Arexvy as well as Eisai’s Alzheimer’s therapy Leqembi (lecanemab).Arexvy became the first…
HOME > ACADEMIA
ACADEMIA
- Avigan Fails to Hit Statistical Significance in COVID-19 Trial: Fujita Health Univ.
July 13, 2020
- Univ. of Tokyo, Biogen Expand Neurological Research Program for 2 Years
July 9, 2020
- Kyoto University, NIBIOHN to Join Forces on Drug Discovery
July 8, 2020
- Nobel Laureate Honjo Sues Ono over Opdivo Royalties, Demands 22.6 Billion Yen
June 22, 2020
- NIID Aims to Start Preclinical Trials for Coronavirus Vaccines in Autumn: Flu Center Director
June 10, 2020
- Remdesivir Not Used as Severe Cases Decreased, Avigan/Alvesco Given to Several Dozen Patients: TMDU Hospital
June 5, 2020
- AnGes/Osaka Univ. Plan Small COVID-19 Vaccine Study from July, Larger One from September
June 5, 2020
- Kyoto Univ. to Launch Alzheimer’s Trial: iPSC-Based Drug Repositioning Project
June 5, 2020
- Japan to Join NIH’s Remdesivir-Baricitinib Combo Trial for COVID-19
June 1, 2020
- 26 Patients Enrolled in Alvesco’s Novel Coronavirus Trial: NCGM
June 1, 2020
- Nagasaki Univ. to Launch Clinical Trial for Nelfinavir for COVID-19
May 28, 2020
- Most Mild COVID-19 Patients Recovered on Avigan, but Careful Interpretations Needed for Single-Arm Study: Interim Report
May 27, 2020
- Discontinued HIV Med Nelfinavir Hits Limelight as Potential COVID-19 Treatment
May 26, 2020
- Avigan Interim Analysis Not Intended to Determine Efficacy, Research Sponsor Says on Reports
May 21, 2020
- Infection Society's Updated COVID-19 Guide Includes Information on Veklury
May 15, 2020
- Investigator Calls for Early Listing of Zolgensma in Japan
May 12, 2020
- Univ. of Tokyo Starts Testing Avigan Plus Futhan for COVID-19
May 11, 2020
- 5-Year Cancer Survival Rates Up 2 Points to 64.1%: NCC
April 17, 2020
- Gunma Univ. Hospital Plans Clinical Research Covering Hydroxychloroquine
April 13, 2020
- BCG’s Efficacy in COVID-19 Not Yet Confirmed: Japan Vaccine Society
April 6, 2020
ページ
A doctor member of the Central Social Insurance Medical Council (Chuikyo) on September 20 traded barbs with pharma leaders over…
The Ministry of Health, Labor and Welfare (MHLW) on September 19 proposed restructuring the Japanese generic industry by restricting the…
The Ministry of Health, Labor and Welfare (MHLW) plans to no longer require the implementation of additional PI clinical studies…
IntroductionCommercial transformation is a top priority for pharma leaders in Japan and rightfully so. In a market with low single…
In the run-up to FY2024 budget requests this summer, there were growing hopes in the pharmaceutical industry that the government's de-facto cap on increases in social security spending would finally be lifted. That did not happen, despite strong calls from…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…